While several studies have demonstrated that the Oncotype DX Recurrence Score can help predict locoregional recurrence in patients with hormone receptor-positive breast cancer, it’s less clear whether ...

There's a long-standing concern among oncologists that many women with ductal carcinoma in situ (DCIS), a potential precursor to invasive breast cancer, receive more treatment than they need. The ...

Please provide your email address to receive an email when new articles are posted on . A novel AI multimodal model outperformed Oncotype DX in overall distant recurrence rate at 15 years. Additional ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

Highlights From the 2025 Pediatric Oncology East and Mediterranean Biennial Conference: Advancing Pediatric Oncology Across the Eastern Mediterranean Breast cancer imposes a substantial disease burden ...

Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.

SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, a new analysis of a ...